 Specifically, subjects will participate in a 3-month, two-group, randomized intervention, where one group n10 will take 1 gramday RBAC and the other group n10 will take a placebo to compare differences in outcomes between the two groups. The results of the study are intended to address the multi-faceted physiological problems of NAFLD patients by testing the efficacy of a nutritional supplement intervention on multiple outcomes in this population. 